An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Jacob Sands, MD
Julia Rotow, MD
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Charles Turck, PharmD, BCPS, BCCCP
Laura Alder, MD
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Aaron Lisberg, MD
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Alex Spira, MD, PhD, FACP
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Thomas Egenod, MD
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Marina Garassino, MD
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Aakesh Desai, MD, MPH
Managing Immunotherapy Toxicities in Lung Cancer Patients
Aliyah Pabani, MD
Recognizing the Role of Capmatinib for METex14 in NSCLC
Edward B. Garon, MD, MS
Exploring Advances in Treatment: A Step Forward in Small Cell Lung Cancer
Millie Das, MD
Investigating Immunotherapy & Its Role in NSCLC
Mark Awad, MD, PhD
Evaluating Biomarkers at Work in NSCLC
Assessing Quality of Care: Implementing a Lung Screening Program
Andrea B. McKee, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.